SymbolFLGT
NameFULGENT GENETICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryMedical Specialities
Address4978 SANTA ANITA AVENUE,SUITE 205, TEMPLE CITY, California, 91780, United States
Telephone+1 626 350-0537
Fax
Email
Websitehttps://www.fulgentgenetics.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001674930
Description

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgents product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Additional info from NASDAQ:
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgents product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

2026-05-04 11:00

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

Read more
2026-05-01 11:00

Fulgent Reports First Quarter 2026 Financial Results

Read more
2026-04-28 20:52

Gao Hanlin 🔴 sold 1.6K shares of Fulgent Genetics, Inc. (FLGT) at $16.31 Transaction Date: Apr 26, 2026 | Filing ID: 187451

Read more
2026-04-28 20:52

Xie Jian 🔴 sold 4.4K shares of Fulgent Genetics, Inc. (FLGT) at $16.31 Transaction Date: Apr 26, 2026 | Filing ID: 187448

Read more
2026-04-28 20:51

Kim Paul 🔴 sold 2.7K shares of Fulgent Genetics, Inc. (FLGT) at $16.31 Transaction Date: Apr 26, 2026 | Filing ID: 187445

Read more
2026-04-16 11:30

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

Read more
2026-03-31 17:58

New Form 4/A - Fulgent Genetics, Inc. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001302110-26-000014 <b>Size:</b> 13 KB

Read more
2026-03-31 17:57

New Form SCHEDULE 13D/A - Fulgent Genetics, Inc. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001302110-26-000013 <b>Size:</b> 23 KB

Read more
2026-03-25 23:00

FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.

Read more
2026-03-17 22:00

FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Read more